PT1a,bN0M0 Breast Carcinoma Characteristics and Management: the French ODISSEE Cohort

被引：1
|
作者：
Dalenc, F. [1 ]
Llorca, F. Penault [2 ]
Cohen, M. [3 ]
Houvenaeghel, G. [4 ]
Piat, J. M. [5 ]
Liegeois, P. [5 ]
Puyuelo, L. [6 ]
Suchaud, J. P. [7 ]
Zouai, M. [8 ]
Belkacemi, Y. [9 ]
机构：
[1] Inst Claudius Regaud, Toulouse, France
[2] Inst Jean Perrin, Clermont Ferrand, France
[3] Private Inst, Aubagne, France
[4] Inst Paoli Calmettes, Marseille, France
[5] Clin Orangerie, Strasbourg, France
[6] Clin Union, St Jean, France
[7] Hop Roanne, Roanne, France
[8] Inst Marie Curie, Valence, France
[9] Hop Princesse Grace, Monaco, Monaco
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71608-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S379 / S380
页数：2
相关论文
共 50 条
  • [1] PT1a,bN0M0 breast carcinoma characteristics and management: The French ODISSEE cohort
    Dalenc, F.
    Penault-Llorca, F. M.
    Cohen, M.
    Houvenaeghel, G.
    Piat, J.
    Liegeois, P.
    Puyuelo, L.
    Suchaud, J.
    Zouai, M. E. H.
    Beauclair, S.
    Belkacemi, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] FOR WHICH PT1A, BN0M0 HORMONE RESPONSIVE INVASIVE BREAST CARCINOMAS COULD ENDOCRINE THERAPY BE AVOIDED?
    Perrin, C.
    Edeline, J.
    Leseur, J.
    Lavoue, V.
    Tas, P.
    Mesbah, H.
    Lefeuvre-Plesse, C.
    Gedouin, D.
    Penault-Llorca, F.
    Kerbrat, P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 105 - 105
  • [3] pT1a, bpN0M0 breast cancer: clinicopathological characteristics and their impact on treatment decision. Central review of the prospective ODISSEE cohort
    Lacroix-Triki, M.
    Radosevic-Robin, N.
    Louis, B.
    Roche-Comet, I.
    Soubeyrand, M-S
    Bourgeois, H.
    Chauvet, M-P
    Fourrier-Reglat, A.
    Gligorov, J.
    Peyrat, J-P
    Dalenc, F.
    Belkacemi, Y.
    Penault-Llorca, F.
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Clinicopathological Characterization of pT1a,b pN0 M0 Breast Cancer - Impact on Treatment Decision in the ODISSEE Cohort
    Lacroix-Triki, M.
    Radosevic-Robin, N.
    Louis, B.
    Roche-Comet, I.
    Soubeyrand, M-S
    Mely, E.
    Dalenc, F.
    Belkacemi, Y.
    Penault-Llorca, F.
    [J]. MODERN PATHOLOGY, 2014, 27 : 62A - 62A
  • [5] Clinicopathological Characterization of pT1a,b pN0 M0 Breast Cancer - Impact on Treatment Decision in the ODISSEE Cohort
    Lacroix-Triki, M.
    Radosevic-Robin, N.
    Louis, B.
    Roche-Comet, I.
    Soubeyrand, M-S
    Mery, E.
    Dalenc, F.
    Belkacemi, Y.
    Penault-Llorca, F.
    [J]. LABORATORY INVESTIGATION, 2014, 94 : 62A - 62A
  • [6] Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?
    Perrin, Christophe
    Frenel, Jean-Sebastien
    Edeline, Julien
    Robert, Marie
    Tas, Patrick
    Lefeuvre-Plesse, Claudia
    Gourmelon, Carole
    Le Du, Fanny
    Campone, Mario
    Kerbrat, Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study
    Dalenc, Florence
    Penault-Llorca, Frederique
    Cohen, Monique
    Houvenaeghel, Gilles
    Piat, Jean-Marc
    Liegeois, Philippe
    Puyuelo, Laurent
    Suchaud, Jean-Philippe
    Zouai, Mohammed
    Lacroix-Triki, Magali
    Radosevic-Robin, Nina
    Benkanoun, Chahinez
    Attar-Rabia, Hanane
    Chauvet, Marie-Pierre
    Gligorov, Joseph
    Belkacemi, Yazid
    [J]. CLINICAL BREAST CANCER, 2017, 17 (02) : 107 - 116
  • [8] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Petrelli, Fausto
    Barni, Sandro
    [J]. MEDICAL ONCOLOGY, 2011, 28 (02) : 401 - 408
  • [9] Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis
    F. Petrelli
    S. Barni
    [J]. Medical Oncology, 2012, 29 : 2586 - 2593
  • [10] Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate
    Fausto Petrelli
    Sandro Barni
    [J]. Medical Oncology, 2011, 28 : 401 - 408
12345